Target intelligence / Profile preview

Influenza B virus hemagglutinin (HA) (HA)

Target
HA
Molecular classification
Viral surface glycoprotein, Type I membrane protein, Receptor-binding protein, Fusion protein
01

Overview

Influenza B hemagglutinin (HA) is a class I viral fusion protein and the primary surface antigen of the Influenza B virus, essential for viral infectivity (UniProt P03460). It functions by binding to terminal sialic acids on host cell surface glycoproteins, triggering receptor-mediated endocytosis, and subsequently mediating the fusion of the viral envelope with the endosomal membrane at low pH.

The BK-FLU mRNA construct, also known as "BNT161", is a nucleoside-modified messenger RNA vaccine candidate that encodes the HA protein of selected Influenza B strains. Upon administration, host cells translate the mRNA into HA protein, which then stimulates the immune system to produce neutralizing antibodies and activate T-cell responses. This target is critical for seasonal influenza prevention, although its high rate of mutation in the globular head region necessitates frequent vaccine updates to maintain efficacy against circulating lineages such as Victoria and Yamagata. Biotech development focuses on both increasing the breadth of the immune response and improving the speed of vaccine production through mRNA platforms.

Other names
HemagglutininInfluenza B HAHA1/HA2 subunitSurface glycoproteinBK-FLU antigen
02

Mechanism of action

Induction of neutralizing antibodies that block viral attachment to sialic acid receptors and prevent pH-dependent membrane fusion.

03

Biological functions

Viral entryReceptor bindingMembrane fusionImmune response induction
04

Disease associations

InfectionSeasonal influenza
05

Safety considerations

Antigenic drift leading to vaccine mismatchInjection site reactions (pain, swelling)Systemic reactogenicity (fever, fatigue)Potential for suboptimal immune response in elderly populations
06

Interacting drugs

BNT161 (BK-FLU)

5 more in the full profile.

07

Biomarkers

Hemagglutination inhibition (HAI) titersMicroneutralization (MN) titersHA-specific IgG and IgA levelsT-cell response (IFN-gamma production)

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Influenza B virus hemagglutinin (HA) (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza B virus hemagglutinin (HA) (HA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call